Patents Assigned to Rockefeller University
  • Broadly-neutralizing anti-HIV antibodies
    Patent number: 10047146
    Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: August 14, 2018
    Assignee: The Rockefeller University
    Inventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
  • Amyloid protofibril antibodies and methods of use thereof
    Patent number: 10035847
    Abstract: The invention relates to methods for obtaining antibodies that recognize amyloid protofibrils and antibodies that recognize one or more amyloid protofibrils. Also provided are methods of using the antibodies to prevent or inhibit amyloid disease in a subject, to diagnose amyloid disease in a subject, and to detect amyloid protofibrils in a sample.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: July 31, 2018
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: W. Vallen Graham, Thomas P. Sakmar
  • INDOLOTRYPTOLINE ANTICANCER AGENTS
    Publication number: 20180193321
    Abstract: Indolotryptoline compounds of the general structure: are disclosed. In these compounds R1 is chosen from hydrogen, halogen and OH; R2 is (C1-C4)alkoxy; and R3 is chosen from hydrogen and halogen The compounds are useful for treating cancer.
    Type: Application
    Filed: July 1, 2016
    Publication date: July 12, 2018
    Applicant: The Rockefeller University
    Inventors: Sean BRADY, Daniel MONTIEL
  • Anti-Inflammatory Polypeptides
    Publication number: 20180179284
    Abstract: This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.
    Type: Application
    Filed: December 18, 2017
    Publication date: June 28, 2018
    Applicant: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Andrew Pincetic
  • Broadly Neutralizing Anti-HIV Antibodies and Epitope Therefor
    Publication number: 20180171001
    Abstract: The present invention relates to broadly neutralizing anti-HIV-1 antibodies and isolated antigens. Also disclosed are related methods and compositions.
    Type: Application
    Filed: January 30, 2015
    Publication date: June 21, 2018
    Applicants: The Rockefeller University, California Institute of Technology
    Inventors: Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf, Johannes Scheid
  • Anti-Tumor Agents and Methods of Use
    Publication number: 20180171021
    Abstract: The present invention relates to anti-tumor agents that target certain tumor-associated macrophages. Also disclosed are methods of using such agents in treatment of cancer.
    Type: Application
    Filed: June 1, 2016
    Publication date: June 21, 2018
    Applicant: The Rockefeller University
    Inventors: Mikael KARLSSON, Jeffrey V. RAVETCH
  • TREATMENT AND DIAGNOSIS OF MELANOMA
    Publication number: 20180153833
    Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
    Type: Application
    Filed: January 26, 2018
    Publication date: June 7, 2018
    Applicant: The Rockefeller University
    Inventors: Sohail F. Tavazoie, Nora Pencheva
  • Treatment and diagnosis of melanoma
    Patent number: 9962348
    Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: May 8, 2018
    Assignee: The Rockefeller University
    Inventors: Sohail F. Tavazoie, Nora Pencheva
  • IMMUNE COMPLEX
    Publication number: 20180117139
    Abstract: The present invention relates to immunogenic immune complexes, related compositions, and related methods. This invention addresses the above-described un-met need by providing an immune complex (IC) or immune complexes (ICs), which take advantages of Type II Fc receptor (FcR) interactions and signaling to elicit broader and more potent protective immune responses. In one aspect, the invention provides an immune complex comprising an antigenic agent and an isolated protein. The protein comprises an IgG Fc region and is capable of binding to a Type II Fc receptor. Preferably, the protein is an antibody or an Fc region-containing fragment thereof.
    Type: Application
    Filed: March 21, 2016
    Publication date: May 3, 2018
    Applicant: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Taia Wang, Jad Mamaary
  • Treatment of pancreatic and related cancers with 5-acyl-6,7-dihydrothieno[3,2-c]pyridines
    Patent number: 9943507
    Abstract: Methods for inhibiting the growth of pancreatic cancer cells or other cancer cells driven by Sonic hedgehog are disclosed.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: April 17, 2018
    Assignees: Memorial Sloan-Kettering Cancer Center, The Rockefeller University
    Inventors: Marilyn D. Resh, Joseph Fraser Glickman, Elissaveta Petrova, Ouathek Ouerfelli
  • Human Immunodeficiency Virus Neutralizing Antibodies and Methods of Use Thereof
    Publication number: 20180079800
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Application
    Filed: September 29, 2017
    Publication date: March 22, 2018
    Applicants: The Rockefeller University, California Institute of Technology
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • bacteriophage lysins for detection and treatment of gram positive bacteria
    Patent number: 9914915
    Abstract: The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: March 13, 2018
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: Vincent A. Fischetti, Jonathan Schmitz, Daniel Gilmer, Chad Euler
  • Dimeric bacteriophage lysins
    Patent number: 9914916
    Abstract: The present invention provides isolated dimeric Streptococcus-specific phage lysins having two Streptococcus-specific phage lysin monomers covalently linked to each other, and having killing activity against one or more Streptococcus bacteria. Also provided for are pharmaceutical compositions of dimeric lysins and their use in therapeutic treatment or alleviation of infections or bacterial colonizations. The dimeric lysins may also be used to decontaminate porous and non-porous surfaces or devices.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: March 13, 2018
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: Vincent A. Fischetti, Gregory Resch
  • Anti-Inflammatory Polypeptides
    Publication number: 20180051087
    Abstract: This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.
    Type: Application
    Filed: March 4, 2016
    Publication date: February 22, 2018
    Applicant: ROCKEFELLER UNIVERSITY (THE)
    Inventors: Jeffrey V. Ravetch, Andrew Pincetic
  • Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120
    Patent number: 9890207
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: February 13, 2018
    Assignees: California Institute of Technology, The Rockefeller University
    Inventors: Ron Diskin, Pamela J. Bjorkman, Michel Nussenzweig, Johannes Scheid
  • Antibodies targeting HIV escape mutants
    Patent number: 9879068
    Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) broadly neutralizing antibodies having improved potency and breadth for neutralizing a range of HIV strains. Combinations of broadly neutralizing antibodies can also improve potency over a single antibody composition.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: January 30, 2018
    Assignees: California Institute of Technology, The Rockefeller University
    Inventors: Ron Diskin, Anthony P. West, Michel C. Nussenzweig, Pamela J. Bjorkman
  • ANTI-MERTK AGONISTIC ANTIBODIES AND USES THEREOF
    Publication number: 20180002444
    Abstract: The present disclosure provides antibodies that specifically bind to Mer Tyrosine Kinase (MERTK) (e.g., human MERTK, or both human and mouse MERTK) and compositions comprising such antibodies, wherein said antibody agonizes MERTK signaling on endothelial cells. The present disclosure also provides methods for treating cancer, by administering an antibody that specifically binds to MERTK and agonizes MERTK signaling on endothelial cells.
    Type: Application
    Filed: December 21, 2015
    Publication date: January 4, 2018
    Applicant: The Rockefeller University
    Inventors: Sohail Tavazoie, Nils Halberg, Masoud Tavazoie
  • TREATMENT OF ANGIOGENESIS DISORDERS
    Publication number: 20170362664
    Abstract: This invention concerns pathological angiogenesis and cancer, related treatment methods, and related compositions. Also disclosed are related diagnosis kits and methods.
    Type: Application
    Filed: June 22, 2017
    Publication date: December 21, 2017
    Applicant: The Rockefeller University
    Inventors: Sohail Tavazoie, Nils Halberg, Kim Png
  • Anti-inflammatory polypeptides
    Patent number: 9845358
    Abstract: This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: December 19, 2017
    Assignee: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Andrew Pincetic
  • Compositions and methods for altering second messenger signaling
    Patent number: 9840533
    Abstract: The present disclosure provides, among other things, novel cyclic-GMP-AMP (cGAMP) analogs, mimics, mimetics and variants, and compositions and kits thereof; methods of using the compounds as described herein for treating cancer, and immune disease, disorders, or conditions; methods of using the compounds as described herein for modulating cGAS and STING; and methods of designing or characterizing a cGAS modulator.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: December 12, 2017
    Assignees: Memorial Sloan Kettering Cancer Center, Rutgers, The State University of New Jersey, The Rockefeller University, University of Bonn
    Inventors: Dinshaw Patel, Thomas Tuschl, Manuel Ascano, Jr., Yang Wu, Yizhou Liu, Winfried Barchet, Gunther Hartmann, Thomas Zillinger, Roger Jones, Barbara L. Gaffney, Pu Gao